Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextran 70 + glucose (commonly referred to as Dextran 70 in 5% Dextrose) is a sterile, non-pyrogenic intravenous solution used as a plasma volume expander. It consists of dextran 70, a high-molecular-weight branched polysaccharide (average molecular weight of 70,000 Daltons) produced by the fermentation of sucrose by *Leuconostoc mesenteroides*, and glucose (dextrose). The formulation acts as a colloid, increasing the oncotic pressure of the blood and pulling water from the extravascular space into the blood vessels. This expansion of plasma volume improves hemodynamics, cardiac output, and tissue perfusion in patients suffering from hypovolemic shock due to hemorrhage, surgery, or trauma. While it is included on the WHO List of Essential Medicines, its clinical use has declined in favor of other crystalloids and colloids due to risks of anaphylaxis, renal dysfunction, and interference with blood cross-matching and coagulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextran 70 + glucose.